Metabolic / GLP-1

Exenatide

Also: Byetta · Bydureon · Exendin-4

The first approved GLP-1 receptor agonist, originally found in Gila monster saliva; lowers blood sugar and modestly reduces weight.

Discussion

Overview

What it is

Synthetic exendin-4, approved for type 2 diabetes as a twice-daily (Byetta) or weekly (Bydureon) injection. Weight loss is smaller than with semaglutide or tirzepatide.

Common forms

Twice-daily injection (Byetta)Weekly injection (Bydureon BCise)

Mechanism

How it works

Activates GLP-1 receptors: increases insulin release when glucose is high, lowers glucagon, slows stomach emptying and reduces appetite.

GLP-1 receptor agonismGlucose-dependent insulin releaseSlower gastric emptying

↓Blood glucose

↓Appetite

↓Stomach emptying rate

Hormonal impact

↑Insulin

↓Glucagon

Evidence

What the research supports

Lowers HbA1c in type 2 diabetesstrong

Modest weight loss (about 2–4 kg)moderate

Safety

Side effects & interactions

Side effects

Nausea
Vomiting
Injection-site nodules (weekly form)
Pancreatitis serious
Kidney injury from dehydration serious
Thyroid C-cell tumor warning (weekly form; avoid with MEN2 or medullary thyroid cancer history) serious

Medications

Insulin / sulfonylureasmoderateHigher risk of low blood sugar.
WarfarinmoderateINR increases reported; monitor.
Oral drugs needing fast absorptionminorSlowed stomach emptying delays absorption.

Stacking

Combines with

Pairs well

Nothing specific.

Avoid combining

Other GLP-1 drugsDuplicate therapy.

Community

Discussion

Experiences from people who have tried Exenatide. Anecdotes are not medical advice.

Loading discussion…